---
Hematological Oncology,Volume 36, Issue 1, Page 116-120, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 14, 2017 Category: Hematology Source Type: research
Relationship between response rates and median progression ‐free survival in non‐Hodgkin's lymphoma: A meta‐analysis of published clinical trials
Abstract
Demonstration of clinical effectiveness of a non‐Hodgkin's lymphoma (NHL) treatment generally involves determination of progression‐free survival (PFS). However, the long evaluation time of PFS limits its utility to make timely decisions in drug development. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in NHL. A database was systematically developed from 513 identified NHL trials reported from 1996 to 2015. Potential predictors of the relationship between response rates and PFS were evaluated, including age, sex, treatment, percentage of trea...
Source: Hematological Oncology - July 14, 2017 Category: Hematology Authors: Naveen Mangal, Ahmed Hamed Salem, Mengyao Li, Rajeev Menon, Kevin J. Freise Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Epstein ‐Barr virus lytic cycle involvement in diffuse large B cell lymphoma
Abstract
Epstein‐Barr virus (EBV)‐mediated B cell transformation is achieved predominantly through the action of latent proteins, but recent evidence suggests that lytic EBV replication has also a certain pathogenic role in lymphomagenesis, at least in the early phases of cell transformation. Particularly, in diffuse large B cell lymphoma (DLBCL), the EBV lytic cycle is by and large unexplored, so to disclose lytic cell contribution to lymphomagenesis, our aim was to evaluate viral early and late lytic gene expression in relation to several immune response markers in a series of EBV+ DLBCL from Argentina. An unexpected...
Source: Hematological Oncology - July 14, 2017 Category: Hematology Authors: Melina Cohen, Aldana Georgina Vistarop, Fuad Huaman, Marina Narbaitz, Fernanda Metrebian, Elena De Matteo, Mar ía Victoria Preciado, Paola Andrea Chabay Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Epstein ‐Barr virus‐negative extranodal “true” natural killer‐cell lymphoma harbouring a KDM6A mutation
Hematological Oncology,Volume 36, Issue 1, Page 328-335, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 10, 2017 Category: Hematology Source Type: research
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B ‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT) lymphoma
Hematological Oncology,Volume 36, Issue 1, Page 49-55, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 10, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 328-335, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 10, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 49-55, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 10, 2017 Category: Hematology Source Type: research
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B ‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT) lymphoma
Abstract
These are the final results of the Ofatumumab in MALT lymphoma study (O‐MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg) followed by 4 doses at 2‐month intervals starting at week 8. According to protocol, a total of 16 patients were recruited (median age 69 years; range 38‐85). Thirty one percent (5/16) of patients had primary gastric MALT lymphoma while the remaining 69% (11/16) presented with extragastric ma...
Source: Hematological Oncology - July 10, 2017 Category: Hematology Authors: Barbara Kiesewetter, Ortrun Neuper, Marius E. Mayerhoefer, Werner Dolak, Julius Lukas, Ingrid Simonitsch ‐Klupp, Markus Raderer Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab
Hematological Oncology,Volume 36, Issue 1, Page 144-149, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 7, 2017 Category: Hematology Source Type: research
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice
Hematological Oncology,Volume 36, Issue 1, Page 210-216, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 7, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 144-149, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 7, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 210-216, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 7, 2017 Category: Hematology Source Type: research
Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab
Abstract
Bendamustine (B) associated with rituximab (R) is widely described in literature for the management of patients with chronic lymphoid leukaemia (CLL) and indolent non‐Hodgkin lymphoma. Safety data regarding late hematotoxicity such as late onset neutropenia (LON) are scarce. The aim of our study was to assess the incidence and to identify risk factors for LON in patients with indolent non‐Hodgkin lymphoma and CLL treated with B and R (B‐R).
One hundred forty five patients were treated with B‐R as first or second line. Patients with neutropenia prior induction treatment, treated beyond second line and relap...
Source: Hematological Oncology - July 7, 2017 Category: Hematology Authors: B. Verriere, L. Gastaud, E. Chamorey, F. Peyrade, E. Deletie, K. Bouredji, D. Quinsat, R. Schiappa, A. Thyss, D. Re Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Smoking and subsequent risk of acute myeloid leukaemia: A pooled analysis of 9 cohort studies in Japan
Hematological Oncology,Volume 36, Issue 1, Page 262-268, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 6, 2017 Category: Hematology Source Type: research
Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study)
Hematological Oncology,Volume 36, Issue 1, Page 202-209, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - July 6, 2017 Category: Hematology Source Type: research
